DEPDC1B promotes colorectal cancer via facilitating cell proliferation and migration while inhibiting apoptosis

References

• Navarro M, Nicolas A, Ferrandez A, et al. Colorectal cancer population screening programs worldwide in 2016: an update. World J Gastroenterol. 2017;23(20):3632–3642.
   PubMed Web of Science ®Google Scholar
• Bultman SJ. Interplay between diet, gut microbiota, epigenetic events, and colorectal cancer. Mol Nutr Food Res. 2017;61(1):1–12.
   Web of Science ®Google Scholar
• Meester RG, Doubeni CA, Lansdorp-Vogelaar I, et al. Colorectal cancer deaths attributable to nonuse of screening in the United States. Ann Epidemiol. 2015;25(3):208–213 e201. DOI:10.1016/j.annepidem.2014.11.011
   PubMed Web of Science ®Google Scholar
• Chittleborough TJ, Kong JC, Guerra GR, et al. Colonoscopic surveillance: quality, guidelines and effectiveness. ANZ J Surg. 2018;88(1–2):32–38.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–337.
   PubMed Web of Science ®Google Scholar
• Novellasdemunt L, Antas P, Li VS. Targeting Wnt signaling in colorectal cancer. A review in the theme: cell signaling: proteins, pathways and mechanisms. Am J Physiol Cell Physiol. 2015;309:C511–C521. DOI:10.1152/ajpcell.00117.2015
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–762. DOI:10.1016/S1470-2045(10)70130-3
   PubMed Web of Science ®Google Scholar
• Seligmann J. Exploring the poor outcomes of BRAF mutant (BRAF mut) advanced colorectal cancer (aCRC): analysis from 2,530 patients (pts) in randomized clinical trials (RCTs). J Clin Oncol. 2015;33(Suppl):abstr 3509.
   Google Scholar
• Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600–mutant colorectal cancer. J Clin Oncol. 2015;33(34):4023–4031. DOI:10.1200/JCO.2015.63.2471
   PubMed Web of Science ®Google Scholar
• Taieb J, Zaanan A, Le Malicot K, et al. Prognostic effect of BRAF and KRAS mutations in patients with stage iii colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial. JAMA Oncol. 2016;2(5):643–653. DOI:10.1001/jamaoncol.2015.5225
   PubMed Web of Science ®Google Scholar
• Douillard JY, Oliner KS, Siena S, et al. Panitumumab–folfox4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–1034. DOI:10.1056/NEJMoa1305275
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–1075. DOI:10.1016/S1470-2045(14)70330-4
   PubMed Web of Science ®Google Scholar
• Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–1315. DOI:10.1016/S1470-2045(15)00122-9
   PubMed Web of Science ®Google Scholar
• Sokol S. A role for Wnts in morpho-genesis and tissue polarity. Nat Cell Biol. 2000;2(7):E124–E125.
   PubMedGoogle Scholar
• Ballon DR, Flanary PL, Gladue DP, et al. DEP-Domain-Mediated regulation of GPCR signaling responses. Cell. 2006;126(6):1079–1093.
   PubMed Web of Science ®Google Scholar
• Peck J, Douglas G IV, Wu CH, et al. Human RhoGAP domain-containing proteins: structure, function and evolutionary relationships. FEBS Lett. 2002;528:27–34.
   PubMed Web of Science ®Google Scholar
• Burchett SA. Regulators of G protein signaling. J Neurochem. 2000;75(4):1335–1351.
   PubMed Web of Science ®Google Scholar
• Wharton KA Jr. Runnin’ with the Dvl: proteins that associate with Dsh/Dvl and their significance to Wnt signal transduction. Dev Biol. 2003;253:1–17.
   PubMed Web of Science ®Google Scholar
• Wong HC, Mao J, Nguyen JT, et al. Structural basis of the recognition of the dishevelled DEP domain in the Wnt signaling pathway. Nat Struct Mol Biol. 2000;7:1178–1184.
   Google Scholar
• Consonni SV, Gloerich M, Spanjaard E, et al. cAMP regulates DEP domain-mediated binding of the guanine nucleotide exchange factor Epac1 to phosphatidic acid at the plasma membrane. Proc Natl Acad Sci. 2012;109:3814–3819.
   PubMed Web of Science ®Google Scholar
• Chen S, Hamm HE. DEP domains: More than just membrane anchors. Dev Cell. 2006;11:436–438. DOI:10.1016/j.devcel.2006.09.011
   PubMed Web of Science ®Google Scholar
• Boudreau HE, Broustas CG, Gokhale PC, et al. Expression of BRCC3, a novel cell cycle regulated molecule, is associated with increased phospho-ERK and cell proliferation. Int J Mol Med. 2007;19:29–39.
   PubMed Web of Science ®Google Scholar
• Figeac N, Pruller J, Hofer I, et al. DEPDC1B is a key regulator of myoblast proliferation in mouse and man. Cell Prolif. 2020 Jan;53(1):e12717.
   PubMed Web of Science ®Google Scholar
• Su YF, Liang CY, Huang CY, et al. A putative novel protein, DEPDC1B, is overexpressed in oral cancer patients, and enhanced anchorage-independent growth in oral cancer cells that is mediated by Rac1 and ERK. J Biomed Sci. 2014;21:67.
   PubMed Web of Science ®Google Scholar
• Shoumin B, Chen T, Du T, et al. High levels of DEPDC1B predict shorter biochemical recurrence‑free survival of patients with prostate cancer. Oncol Lett. 2017;14:6801–6808.
   PubMed Web of Science ®Google Scholar
• Zheng ZX, Zheng RS, Zhang SW, et al. Colorectal cancer incidence and mortality in china, 2010. Asian Pac J Cancer Prev. 2014;15:8455–8460.
   PubMedGoogle Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–562.
   PubMed Web of Science ®Google Scholar
• Samuels Y, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7:561–573. DOI:10.1016/j.ccr.2005.05.014
   PubMed Web of Science ®Google Scholar
• Bisht S, Ahmad F, Sawaimoon S, et al. Molecular spectrum of KRAS, BRAF and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma. Med Oncol. 2014;31:124.
   PubMed Web of Science ®Google Scholar
• Smith CG, Fisher D, Claes B, et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clin Cancer Res. 2013;19:4104–4113. DOI:10.1158/1078-0432.CCR-12-2581
   PubMed Web of Science ®Google Scholar
• Chen X, Guo ZQ, Cao D, et al. Knockdown of DEPDC1B inhibits the development of glioblastoma. Cancer Cell Int. 2020 Jul 15;20:310. DOI:10.1186/s12935-020-01404-7
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu L, Cai J, et al. DEPDC1B enhances migration and invasion of non-small cell lung cancer cells via activating Wnt/β-catenin signaling. Biochem Biophys Res Commun. 2014;450:899–905.
   PubMed Web of Science ®Google Scholar
• Lai CH, Xu K, Zhou J, et al. DEPDC1B is a tumor promotor in development of bladder cancer through targeting SHC1. Cell Death Dis. 2020 Nov 17;11(11):986.
   PubMed Web of Science ®Google Scholar
• Liu X, Li T, Huang X, et al. DEPDC1B promotes migration and invasion in pancreatic ductal adenocarcinoma by activating the Akt/GSK3β/Snail pathway. Oncol Lett. 2020 Nov;20(5):146.
   PubMed Web of Science ®Google Scholar